Physicians' Academy for Cardiovascular Education

NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD

ESC 2017 - Barcelona

3' education - Aug. 27, 2017

ESC 2017 John Eikelboom shares the COMPASS results, in which rivaroxaban plus aspirin, or rivaroxaban alone, was compared against aspirin monotherapy, for long-term secondary prevention in patients with stable CAD or PAD.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ESC 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.

Disclosures

John Eikelboom - McMaster University, Hamilton, ONT, Canada

The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this 3-minute education.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: